Medicine Information

Hemotrax

Name: Hemotrax
Brand: Hemotrax
Rating: 4.5 (117 reviews)

Tablet500 mgAnti-fibrinolyticATC: B02AA02

Generic Name

Tranexamic Acid

Manufacturer

Square Pharmaceuticals Ltd.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
hemotrax 500 mg tablet	৳ 20.00	৳ 200.00

Description

Overview of the medicine

Hemotrax-500 mg tablet is an anti-fibrinolytic medication used to prevent and treat excessive bleeding. It works by inhibiting the breakdown of blood clots, thereby promoting clot stability.

Uses & Indications

Menorrhagia (heavy menstrual bleeding)

Nosebleeds (epistaxis)

Dental extractions in patients with bleeding disorders

Post-operative bleeding (e.g., prostatectomy, tonsillectomy)

Gastrointestinal bleeding

Hereditary angioedema (for prophylaxis)

Dosage

Adults

General dosage: 500 mg to 1000 mg three times daily. For menorrhagia: 1000 mg three times daily for up to 5 days during menstruation. Maximum 4 grams/day.

Elderly

Dose adjustments may be necessary based on renal function. Use with caution.

Renal_impairment

Reduced dosage required based on creatinine clearance (CrCl). E.g., CrCl 30-50 mL/min: 500 mg twice daily; CrCl <30 mL/min: 500 mg once daily.

How to Take

Take orally with or without food. Swallow the tablet whole with water. Do not crush, chew, or break the tablet. Follow your doctor's instructions carefully.

Mechanism of Action

Tranexamic acid competitively inhibits the activation of plasminogen to plasmin, a molecule responsible for the degradation of fibrin clots. By preventing fibrinolysis, it helps to stabilize clots and reduce bleeding.

Pharmacokinetics

Onset

Within 1-2 hours (oral administration).

Excretion

Mainly via renal excretion (over 95% unchanged in urine within 24 hours).

Half life

Approximately 2-11 hours (dose-dependent and renal function dependent).

Absorption

Rapidly absorbed from the gastrointestinal tract; bioavailability is approximately 30-50%. Peak plasma concentrations are reached within 3 hours after oral administration.

Metabolism

Minimally metabolized (less than 5% of the dose); primarily excreted unchanged.

Side Effects

Contraindications

History of thrombosis (e.g., deep vein thrombosis, pulmonary embolism, cerebral thrombosis)
Severe renal impairment (risk of accumulation and toxicity)
Subarachnoid hemorrhage (due to risk of cerebral edema and infarction)
Acquired defective color vision
Hypersensitivity to tranexamic acid or any component of the formulation

Drug Interactions

Oral Contraceptives

Increased risk of thrombosis (blood clots) when used concurrently.

Factor IX complex concentrates

Increased risk of thrombosis.

Thrombolytic agents (e.g., alteplase)

Antagonistic effect, may reduce the efficacy of thrombolytics.

Anticoagulants (e.g., warfarin, heparin)

Careful monitoring required; tranexamic acid acts as an antifibrinolytic, potentially counteracting anticoagulant effects.

Storage

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach and sight of children.

Overdose

Symptoms of overdose may include nausea, vomiting, diarrhea, orthostatic hypotension, and thromboembolic events. Management is supportive and symptomatic; gastric lavage may be considered. Hemodialysis is not effective in removing tranexamic acid.

Pregnancy & Lactation

Pregnancy Category B. Studies in animals have not shown harm, but adequate studies in pregnant women are lacking. Use only if clearly needed and potential benefits outweigh risks. Tranexamic acid is excreted in breast milk; caution advised during lactation.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

10 tablets (1x10 blister)30 tablets (3x10 blister)

Shelf Life

36 months from the date of manufacture

Availability

Available in pharmacies and hospitals nationwide

Approval Status

Approved by DGDA

Patent Status

Generic available

WHO Essential Medicine

Yes

Clinical Trials

Tranexamic acid has been extensively studied in numerous clinical trials establishing its efficacy and safety for various bleeding conditions, including major trauma, postpartum hemorrhage, and elective surgery.

Lab Monitoring

Monitor renal function (creatinine clearance) in patients with impaired kidney function and adjust dose accordingly.
Periodically monitor for signs and symptoms of thrombosis (e.g., D-dimer levels, fibrinogen levels) especially with long-term use.
Ophthalmologic examination for color vision should be performed regularly with long-term continuous use.

Doctor Notes

Assess patient's thrombotic risk factors (e.g., personal or family history of thrombosis, use of estrogen-containing contraceptives) before prescribing.
Adjust dosage in patients with renal impairment to prevent accumulation and potential toxicity.
Advise patients to report any signs of thrombosis or vision changes immediately.
Consider ophthalmologic examination with long-term continuous use for color vision changes.

Patient Guidelines

Take this medicine exactly as prescribed by your doctor.
Do not stop taking the medicine suddenly without consulting your doctor, even if your bleeding stops.
Report any signs of blood clots (e.g., swelling, pain, redness in a leg; sudden shortness of breath; chest pain; sudden vision changes) immediately.
If you experience any changes in your vision, including color vision, discontinue the medicine and consult your doctor.

Missed Dose Advice

If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take a double dose to make up for a missed one.

Driving Precautions

Hemotrax-500 mg may cause dizziness or visual disturbances in some patients. Do not drive or operate machinery until you know how this medicine affects you.

Lifestyle Advice

Maintain adequate hydration.
Avoid prolonged periods of immobility, especially if you have risk factors for blood clots.
Discuss any concerns about bleeding or clotting with your doctor or pharmacist.